Bruno Carlos
Sangro Gómez-Acebo
Catedrático de Universidad
University of California, San Francisco
San Francisco, Estados UnidosUniversity of California, San Francisco-ko ikertzaileekin lankidetzan egindako argitalpenak (3)
2022
-
Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma
Clinical Cancer Research, Vol. 28, Núm. 16, pp. 3537-3545
2021
-
A Real-World Observational Cohort of Patients with Hepatocellular Carcinoma: Design and Rationale for TARGET-HCC
Hepatology Communications, Vol. 5, Núm. 3, pp. 538-547
-
Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study
Journal of Clinical Oncology, Vol. 39, Núm. 27, pp. 2991-3001